Phase 2 Readout~quarter
Phase 2 Readout: remlifanserin
- Drug
- remlifanserin
- Indication
- Alzheimer's disease psychosis
Other upcoming events for ACAD
Phase 3 ReadoutPhase 3 Topline: A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Effi
Phase 3 ReadoutPhase 3 Topline: 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis
Phase 3 ReadoutPhase 3 Topline: A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Phase 3 ReadoutPhase 3 Topline: A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia i
Patent ExpiryPatent/Exclusivity Expiry: SEGLENTIS
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.